Clinical Trial: Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07481734) titled 'Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)' on March 08.

Brief Summary: This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.

Study Start Date: Feb. 02

Study Type: INTERVENTIONAL

Cond...